<DOC>
	<DOCNO>NCT00055835</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin , paclitaxel , gemcitabine , cisplatin , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving chemotherapy radiation therapy , combine chemotherapy radiation therapy , may kill tumor cell . PURPOSE : Phase II trial study effectiveness neoadjuvant gemcitabine , paclitaxel , carboplatin follow cisplatin radiation therapy treat patient locally advanced recurrent carcinoma ( cancer ) urothelium .</brief_summary>
	<brief_title>S0121 , Neoadjuvant Carboplatin , Paclitaxel , Gemcitabine Followed Cisplatin Radiation Therapy Treating Patients With Locally Advanced Recurrent Carcinoma Urothelium</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall survival patient locally advanced recurrent carcinoma urothelium treat neoadjuvant carboplatin , paclitaxel , gemcitabine follow concurrent cisplatin radiotherapy . - Determine feasibility administer regimen patient . - Determine progression-free survival patient treat regimen . - Determine qualitative quantitative toxic effect regimen patient . - Determine response rate ( confirm unconfirmed ) patient treat neoadjuvant regimen treat whole regimen . - Determine proportion patient qualify concurrent cisplatin radiotherapy receive neoadjuvant regimen . - Determine potential value suppressor gene expression analysis ( p53 retinoblastoma gene ) HER2 expression indicator prognosis and/or response patient treat regimen . OUTLINE : This multicenter study . Patients receive neoadjuvant chemotherapy comprise paclitaxel IV 3 hour carboplatin IV 15 minute day 1 gemcitabine IV 30 minute day 1 8 . Treatment repeat every 21 day maximum 3 course absence disease progression unacceptable toxicity . Within 4-8 week completion neoadjuvant chemotherapy , patient receive cisplatin IV 30-60 minute day 1 . Treatment repeat every 21 day maximum 2 course absence disease progression unacceptable toxicity . Patients also undergo concurrent radiotherapy 5 day week 6 week . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 80 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary recurrent invasive carcinoma urothelium Transitional , squamous , mixed cell subtypes allow Primary disease site must urinary bladder urethra Disease confine true pelvis ( T2T4 , N0N3 , M0 ) Must meet least 1 follow criterion : Nodal involvement level bifurcation iliac vessel Medically surgically inoperable Patient refuse cystectomy Measurable nonmeasurable disease Evidence tumor invasion muscularis cystoscopy biopsy detail bladder mapping within past 56 day No extrapelvic metastasis Eligible receive radiotherapy Planned radiotherapy SWOGapproved facility PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Granulocyte count least 1,500/mm^3 Platelet count least low limit normal Hepatic Bilirubin great upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal Creatinine clearance least 60 mL/min OR Creatinine great ULN Gastrointestinal No chronic diarrhea No malabsorption No extensive diverticular disease colon No inflammatory bowel disease No preexist gastrointestinal disorder Other Not pregnant nursing Fertile patient must use effective contraception No active infection require antibiotic No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy patient current diagnosis advance bladder cancer also initial diagnosis No prior systemic chemotherapy except adjuvant therapy recurrent disease complete 6 month ago No prior carboplatin No prior paclitaxel No prior gemcitabine Endocrine therapy Not specify Radiotherapy See Disease Characteristics No prior pelvic radiotherapy Surgery See Disease Characteristics Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>squamous cell carcinoma bladder</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>distal urethral cancer</keyword>
	<keyword>proximal urethral cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>